{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimable due insufficient number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI was not estimable due insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.","id":"OG001","title":"Ado-trastuzumab Emtansine (T-DM1)"}],"paramType":"MEDIAN","populationDescription":"Overall survival (OS) was assessed in the Full Analysis Set at data cut-off date of 21 May 2021.","reportingStatus":"POSTED","timeFrame":"Up to 33 months (data cut-off)","title":"Overall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane","type":"SECONDARY","unitOfMeasure":"months"}